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Abstract  
 
Objectives: To determine incidence and patterns of natural course of cannabis use and disorders as 
well as cohort effects in a community sample of adolescents and young adults. Method: 
Cumulative incidence and patterns of cannabis use and disorders were examined in a prospective 
longitudinal design (mean follow-up period=42 months) in a representative sample (N=2446) aged 
14–24 years at the outset of the study. Patterns of cannabis use, abuse and dependence (DSM-IV) 
were assessed with the Composite International Diagnostic Interview (M-CIDI). Results: (1) 
Cumulative lifetime incidence for cannabis use (at second follow-up): 47%; 5.5% for cannabis 
abuse, 2.2% for dependence. (2) Men used and abused cannabis more often than women. (3) The 
majority of the older participants (18–24 years at baseline) had reduced their cannabis use at 
follow-up, while younger participants (14–17 years at baseline) more often had increased their use 
and developed abuse or dependence. (4) The younger birth cohort (1977–1981) tended to start 
earlier with substance (ab)use compared to the older birth cohort (1970–1977). (5) Cannabis use 
was associated with increasing rates of concomitant use of other licit and illicit drugs. 
Conclusions: Cannabis use is widespread in our sample, but the probability of developing 
cannabis abuse or dependence is relatively low (8%). The natural course of cannabis use is quite 
variable: about half of all cannabis users stopped their use spontaneously in their twenties, others 
report occasional or more frequent use of cannabis.    
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1. Introduction  
 
Across epidemiological studies there is agreement that drug use is widespread among 
adolescents and young adults. Among substances, alcohol and nicotine are generally 
found to be the most frequently used, followed by cannabis, which is by far the most 
widely used illicit substance around the world (Bauman and Phongsavan, 1999). 
Depending on age group, cohort, country and time examined, between 12 and 50% of all 
adolescents and young adults in Europe and North America have tried cannabis at least 
once (Hammer and Vaglum, 1990; Anthony, 1991; Reuband, 1992; Nordlohne et al., 
1993; Anthony et al., 1994; Kraus et al., 1994; Konings et al., 1995; Schumann and Kraus, 
1995; Miller and Plant, 1996; Adlaf et al., 1997; Kraus et al., 1998; Perkonigg et al., 
1998a,b; Weinberg et al., 1998; Bauman and Phongsavan, 1999; Höfler et al., 1999; Ivis 
and Adlaf, 1999; Merrill et al., 1999; Perkonigg et al., 1999; Kokkevi et al., 2000).  
 
In most studies males report a higher lifetime use than females do. Geographic/cultural 
differences in cannabis use have been demonstrated, as well as age and birth cohort 
effects. Highest prevalence of cannabis use have been reported for New Zealand, followed 
by the US and central Europe; lower rates were found in countries at the periphery of 
Europe (e.g. Norway and Greece; Fergusson and Horwood, 2000b; Smart and Ogborne, 
2000). In US high school students, the prevalence of cannabis use rose during the late 
1960s and 1970s, then declined steadily and substantially throughout the 1980s, only to 
rise again markedly after 1992 (Bachman et al., 1998; Bauman and Phongsavan, 1999). 
The comparison of historical trends across various studies and countries is hampered by 
the fact that most studies do not refer to the concept of ‘cohort’ (a group defined by 
calendar year(s) of birth; Neugarten and Datan, 1973) and do not present the years of birth 
of their study participants (e.g. Bachman et al., 1998).  
 
Fewer representative population-based data are available concerning the prevalence of 
abuse and dependence of illicit drugs. Using DSM-III-R criteria a similar rank order was 
found, with highest rates for New Zealand, medium high rates for US (lifetime incidence 
of cannabis dependence in 15–24 year olds: 5.6%), and lowest in Germany (Lewinsohn et 
al., 1992; Anthony et al., 1994; Feehan et al., 1994; Perkonigg et al., 1998a,b, 1999; 
Fergusson and Horwood, 2000a). Males are affected about two to four times as often as 
females (Offord et al., 1996).  
 
Although a considerable number of longitudinal studies have examined risk factors of 
starting, continuing and discontinuing cannabis use (e.g. Kandel and Faust, 1975; 
Newcomb et al., 1986; Kandel and Raveis, 1989; Kendler et al., 1999; Brook et al., 1999), 
remarkably little systematic research is available on the natural course of substance use 
disorders in community samples. Thus, our knowledge about transitions from use to 
patterns of clinically significant abuse and dependence, or regressions from such stages to 
use without disorder or non-use, is quite limited (Perkonigg et al., 1998b; Weinberg et al., 
1998; Nelson and Wittchen, 1998; Cicchetti and Luthar, 1999). These research deficits are 
mainly due to the facts that most studies: (a) employ cross-sectional rather than 
longitudinal designs; (b) do not use specified diagnostic criteria for clinically relevant 
abuse or dependence patterns; (c) focus on the initiation of (ab)use, not on its reduction or 
cessation; (d) are confined either to drug use or to drug abuse and dependence (only a few 
studies take ‘recreational’ (nonpathologic) use as well as clinical criteria into account; 
Glantz, 1992; Kandel and Davies, 1992; Chen and Kandel, 1998).  
 
Nevertheless there seems to be agreement that in comparison to other illicit drugs, only a 
small proportion of all lifetime cannabis users go on to develop clinically significant 
patterns of cannabis abuse or dependence (Weinberg et al., 1998; Perkonigg et al., 1999); 
cannabis as a substance in itself might not be linked to a strong risk of developing a 
dependence syndrome. The relative rarity of clinically significant dependence syndrome 
in cannabis users, even despite continuing regular use, and the research evidence that 
cannabis use tends to be reduced or terminated with advancing age has led many 
researchers to describe the predominant pattern of cannabis use as ‘transient recreational 
use’ with no major risks and a high rate of spontaneous remission. The major risk for 
initiation of cannabis use seems to be completed for the most part by age 20, and it seems 
that about 60% of all cannabis users spontaneously stop their use between ages 23 and 30 
years due to changes in social roles (work, marriage, parenthood) that are felt to be 
incompatible with cannabis use (Kandel and Faust, 1975; Kandel and Logan, 1984; 
Silbereisen, 1997; Hammer and Vaglum, 1990; Johnston et al., 1992; Chen and Kandel, 
1998).  
 
Yet this description does conflict with a considerable body of other studies that have 
pointed to the fact that of cannabis users who progress to regular use, the majority reveal 
extended patterns of regular use for at least one year, associated with gradually increasing 
dosages and frequencies of use as well as increasing risks to use other illicit drugs, such as 
amphetamines, hallucinogens, stimulants and opiates (Merrill et al., 1999; Perkonigg et 
al., 1999; Fergusson and Horwood, 2000a,b). But it may well be that these less optimistic 
data describe the situation in subjects before they make social transitions in their mid or 
late twenties. A lack of prospective-longitudinal studies makes it difficult to decide which 
description of use and abuse patterns is more accurate for the current situation.  
 
The Early Developmental Stages of Psychopathology Study (EDSP; Wittchen and Nelson, 
1998; Lieb et al., 2000), a prospective-longitudinal community-study, examined the 
natural course of cannabis use in a representative sample of 14–24 year olds in Munich, 
Germany. Cannabis use results from the EDSP-baseline and 20 months prospective data 
for the younger cohort (initially aged 14–17 years) have already been presented 
(Perkonigg et al., 1998b, 1999; Höfler et al., 1999).  
 
The focus of this paper is to describe the natural course of cannabis use, abuse and 
dependence over about 4 years in a German sample of adolescents and young adults, aged 
14–24 at baseline (birth cohorts 1970–1981), highlighting gender, age and cohort effects. 
The following questions will be examined:  
 
1. What is the age of onset of cannabis use, abuse and dependence?  
2. How prevalent is cannabis use in adolescence and young adulthood?  
3. How prevalent is cannabis abuse and dependence according to DSM-IV criteria?  
4. How stable are the patterns of cannabis use, abuse and dependence across time, with 
emphasis on increases, reductions and spontaneous remissions?  
5. To what degree is cannabis use associated with the use of other licit and illicit 
substances? Is the cessation of cannabis use accompanied by a compensative increase in 
the use of other drugs or by a decrease?   
 
2. Method  
 
The Early Developmental Stages of Psychopathology Study (EDSP; Wittchen et al., 1998; 
Lieb et al., 2000) explores the prevalence, incidence, comorbidity, risk factors, protective 
factors and 4-year course of mental disorders, with specific emphasis on substance-use 
disorders in a representative general population sample. The study is based on three 
waves, the first conducted in 1995 (t0), the second in 1996–97 (t1: only the younger 
cohort was assessed), and the third in 1998–99 (t2: again with the total sample).  
 
2.1. Baseline sample and follow-up investigations  
 
The sample was drawn randomly from the 1994 government registries of residents in 
metropolitan Munich. A total of 3021 participants aged 14–24 years (birth cohorts 1970–
1981) were successfully interviewed at baseline, resulting in a response rate of 71%. Since 
the study was designed with a special interest in early stages of substance use disorders, 
14–15 year olds were sampled at twice the probability of 16–21 year olds, and 22–24 year 
olds were sampled at half the probability. At baseline, almost three-quarters of the 
participants were students, 36% at the secondary level and 26% at university, and 20% of 
the participants were employed. Nearly two-thirds (62%) were living with their parents, 
23% were living alone, and 12% were living with their partner/spouse. The majority of the 
respondents were classified as middle class (59%), reflecting the population of Munich.  
 
Two follow-up investigations were completed after the initial baseline assessment, 
covering an overall period of 42 months (range: 34–50 months). The first follow-up (t1) 
was conducted in 1996/1997 and confined to the younger subsample (aged 14–17 years at 
baseline); 1228 interviews were completed, giving a follow-up response rate of 88%. The 
second follow-up (t2) included all baseline respondents and was conducted in 1998–99, an 
average of 42 months after the baseline investigation (range 34–50 months); the response 
rate was 84% (N=2548). Of these, 102 participants did not want to respond to questions 
about illicit drug use at t0, t1 or t2. Therefore, our dataset is N=2446 with regard to the 
longitudinal development of cannabis use/abuse across the entire study period: 1101 
participants in the younger cohort (aged 14–17 years baseline, born between 1977 and 
1981), and 1345 in the older cohort (aged 18–24 years at baseline, born between 1970 and 
1977). Data from all three assessments are used in this paper. Noteworthy changes in 
sociodemographic characteristics from baseline to second follow-up were only found for 
school/employment status (t2: secondary school: 13%, employed: 36%) and living 
arrangements (with parents: 40%; with partner: 23%).  
 
2.2. Measures  
 
Face-to-face computer-assisted interviews were administered by professional health 
interviewers and clinical psychologists at baseline and at the two follow-ups. Diagnostic 
assessments (t0–t1–t2) were based on the Munich version of the Composite International 
Diagnostic Interview (M-CIDI; Wittchen and Pfister, 1997). At baseline, lifetime and past 
12 month substance use, substance use disorders and other mental disorders were assessed 
according to DSM-IV criteria. In both follow-up investigations, substance use and 
diagnoses during the follow-up period(s) and for the previous 12 months were evaluated. 
The M-CIDI is an updated version of the World Health Organization’s CIDI version 1.2 
(WHO-CIDI; World Health Organization, 1990), which incorporates questions to cover 
DSM-IV (American Psychiatric Association, 1994) and ICD-10 criteria. The reliability 
and procedural validity of the M-CIDI has been established (Lachner et al., 1998; Reed et 
al., 1998). The assessment of cannabis use, abuse and dependence have been 
comprehensively described elsewhere (Perkonigg et al., 1998a).  
 
2.3. Data analysis  
 
In line with the WHO–CIDI conventions (World Health Organization, 1990; Lachner et 
al., 1998), four mutually exclusive patterns of drug use were considered (never; 1 time; 2–
4 times; 5 or more times). Additionally, the category of the ‘5+ times’ users was 
subdivided into those with ‘considerable’ use (participant never consumed more than two 
joints during one week) or ‘heavy’ use (participant consumed at least three joints during 
one week) according to their peak cannabis- use-per-week period. At second follow-up, 
the cumulative lifetime consumption of cannabis was assessed: those subjects classified as 
having a ‘considerable’ lifetime use on average had consumed cannabis 13–50 times 
(median; 19.5% 5–12 times, 36.1% 13–50 times, 12.1% 51–100 times, 8.4% 101–150 
times, 6.2% 151–200 times, 6.1% 201–365 times and 11.6% > 365 times) and those 
classified as having a ‘heavy’ lifetime use actually had an average use of > 365 times 
(median: 82.5%, only few subjects in this group had consumed less, the minimum being 
5–12 times).  
 
Lifetime prevalence at baseline denotes the weighted rate of occurrence of a pattern of use 
or diagnosis in the total sample or subsamples, and it covers the respondents’ lifetime 
period prior to the assessment at baseline. Follow-up incidence of cannabis use, abuse and 
dependence was defined as new outcomes during the follow-up period (t0 to t2) among 
non-users at baseline. Cumulative lifetime incidence was calculated by adding baseline, t1 
and t2 follow-up incident cases. Twelvemonth prevalence rates at follow-up refer to the 
prevalence of drug use, abuse or dependence during the year preceding the t2-follow-up 
interview.  
 
To account for different sampling probabilities for the different age-groups, non-contact 
and non-response, all measures were estimated using weighted data. To account for design 
effects introduced by the use of weighted data, standard errors were estimated using the 
software package STATA (StataCorp., 1999) that applies the Huber–White sandwich 
matrix in this case (Royall, 1986). Survival analyses were used for the examination of age 
of onset data.  
 
Age-specific cumulative lifetime incidences for cannabis use, abuse and dependence were 
estimated with the Kaplan–Meier method (Andersen and Keiding, 1996). Differences 
between curves were assessed with hazard ratios (HR) from the Cox proportional hazards 
model. The proportional hazards assumption, i.e. hazard ratios being independent of age, 
was tested with so-called Schoenfeld residuals (Grambsch and Therneau, 1994). When 
this assumption was violated for cohort differences, a stratified Cox model was used, i.e. 
different curves in age-cohorts were fitted before testing for group differences (Andersen 
and Keiding, 1996). In the case that the assumption was violated for gender differences 
the interaction term female gender×age was added to the model to test whether age is 
differently associated with the outcome for females as compared to males. A hazard ratio 
smaller than one then means that women have an earlier onset, conditional on the event 
that the outcome event is given.  
 
3. Results  
 
3.1. What is the age of onset of cannabis use, abuse and dependence?  
 
Figs. 1–3 show the age-specific cumulative lifetime incidences for use of cannabis, abuse 
and dependence by gender and birth cohort. First use of cannabis was rarely reported 
before the age of 13 years. After that age, there was a steep increase in use. Development 
of abuse and dependence usually occurred after the age of 15 years. While the (cumulative 
lifetime) use of cannabis was still slightly increasing in the participants’ late twenties, 
none of them developed cannabis abuse or dependence after age 22 (women) or 26 years 
(men). Users who developed cannabis abuse did so on average 2.0 years after first use 
(range: 0–10 years), and dependence criteria were fulfilled 2.4 years (mean) after first use 
(range 0–10 years).  
 
Cohort differences in age of onset could only be analyzed for the period 0-21 years, the 
highest age reached by members of the younger cohort. With regard to cannabis use we 
found lower hazard rates in the older cohort (HR=0.61, 95% confidence interval/CI= 
0.53–0.69, P < 0.05). The curve showing the increase of cannabis use was steeper for the 
younger than for the older cohort (Fig. 1). Similarly, the cohort differences visible in Figs. 
2 and 3 were significant for cannabis abuse (HR=0.45, CI=0.33–0.62, P < 0.05), but they 
did not reach significance for dependence (HR=0.74, CI=0.41–1.32). Interaction effects of 
age and cohort were found for use (HR=1.32, CI=1.20–1.44; P < 0.05), abuse (HR=1.31, 
CI=1.08–1.59, P < 0.05) and did not reach significance with regard to dependence 
(HR=1.13, CI=0.72–1.80). The younger cohort (born 1977–81) started earlier than the 
older cohort (born 1970–77) with (ab)use.  
 
Overall, lower hazard rates were found for women with regard to onset of cannabis use 
(gender differences; HR=0.65, CI=0.57–0.74, P < 0.05), cannabis abuse (HR=0.26, 
CI=0.17–0.37, P < 0.05) and cannabis dependence (HR=0.41, CI=0.21–0.79; P < 0.05). 
Interaction effects of age and gender were found for the onset of cannabis use disorders 
(abuse: HR=0.77, CI=0.63–0.95, P < 0.05; dependence: HR=0.65, CI=0.44–0.95, P < 
0.05) but not for first cannabis use (HR=0.97, CI=0.92–1.03). Taken together, these 
results indicate that fewer females than males started to use cannabis and there is no 
evidence for a different age of onset pattern among those who started with use. In contrast, 
among those who fulfilled criteria for disorders, a higher proportion of females started at 
an earlier age. As shown in Figs. 2 and 3, with increasing age, males’ probability of 
developing a substance use disorder showed a stronger increase than females’. In fact, all 
female subjects who were diagnosed with cannabis dependence developed their 
dependence before age 19 years, while men’s incidence rate for dependence continued to 
increase until age 26 years.  
 
3.2. How prevalent is cannabis use?  
 
At baseline (t0), 65.8% of the sample had never used cannabis, 7.0% reported use only on 
a single occasion, 11.2% reported use ‘2-4 times’, 11.2% reported a ‘considerable’ and 
4.7% a ‘heavy use’ (see Table 1: first column). The cumulative lifetime incidence by the 
second follow-up (t0–t1–t2), roughly 4 years later, revealed a substantial decrease in the 
proportion of subjects with no cannabis use ever (53.4%), and a considerable increase in 
the proportion of 5+ users (‘considerable use’: 22.7%; ‘heavy use’ 6.8%; Table 1: second 
column). Of the baseline non-users, 81.2% remained abstinent while follow-up incidence 
results (t2) reveal that 19% started to use cannabis during the follow-up period; there were 
almost equal proportions of new users with rare use (1 time: 3.5%; 2–4 times: 6.2%) and 
with regular use (‘considerable’: 8.3%; ‘heavy’: 0.8%; Table 1: third column). Taking the 
follow-up (t2) 12-month prevalence as a rough measure for outcome and particular 
discontinuation, the fourth column of Table 1 reveals that only one quarter of the entire 
sample had used cannabis during the year preceding the second follow-up, indicating that 
almost 50% of all previous lifetime users had stopped their cannabis use during the past 
12 months.  
 
Regardless of the period considered, men always revealed a significantly higher rates of 
use (Table 2).  
 
The older cohort reported higher cannabis use at baseline, but the cumulative lifetime 
incidence at follow- up, revealed no significant cohort differences in cannabis use. 
Concerning all other follow-up data (i.e. incidence among baseline non-users and 12-
month follow- up prevalence), however, the younger cohort consistently had a higher risk 
of using cannabis (Table 2).  
 
3.3. How prevalent is cannabis abuse and dependence DSM-IV?  
 
At baseline, 2.5% of the sample fulfilled criteria for cannabis abuse (without dependence), 
and 1.4% for dependence (Table 3: first column). The cumulative lifetime incidence at 
follow-up (t2) reveals a substantial increase, with rates of 5.5% for abuse and 2.2% for 
dependence (Table 3: second column). The follow-up incidences among baseline non-
users were low (abuse: 1.8%; dependence: 0.3%; third column), as were follow-up (t2) 12 
-month prevalences (abuse: 3.0%; dependence: 0.6%; fourth column).  
 
Men generally had a higher risk of developing cannabis abuse and dependence (the latter 
did not reach significance with regard to baseline cumulative lifetime incidence and 
follow-up 12-month prevalence; Table 4).  
 
At baseline, the younger cohort had a significantly reduced risk of meeting criteria for a 
DSM-IV cannabis dependence, but – similar to the cohort effects in cannabis use – the 
cumulative incidence data reveal a reversed effect: the younger cohort had overall a 
significantly higher risk of developing cannabis abuse and dependence (the latter is only 
significant with regard to the follow-up prevalence; Table 4). Additionally, all of the nine 
participants who had not used cannabis at baseline but had developed dependence at 
follow-up came from the younger cohort (Table 3: third column).  
 
3.4. How stable are the patterns of cannabis use, abuse and dependence across time?  
 
Table 5 reports the findings on the change over time in cannabis use by cross-tabulating 
cumulative lifetime incidence (until 12 months prior the second follow-up t2) and 12-
months follow-up findings (t2) along with the estimated conditional probabilities (%) for 
four patterns (no use, use without disorder, abuse without dependence, dependence). The 
diagonal values indicate that two patterns were particularly stable in the total sample: 
namely respondents who had never tried cannabis at baseline were most likely to be 
classified as non-users at follow-up (95.4%), and cannabis users without a disorder also 
tended to remain in the same group (44.1%) or to become non-users (54.7%). Half of 
those diagnosed as having had cannabis abuse had improved during the 12-months follow-
up interval — either by going into the ‘user/no disorder’ category (42.8%) or by becoming 
non-users (13.8%); 41.3% remained abusers and 2.2% developed dependence. Of those 
with an initial (cumulative lifetime) dependence, 19.0% remained dependent, 20.6% 
moved to abuse without dependence, while half of this group showed remission (44.2% to 
use without disorder, and 16.2% to no use).  
 
We did not find significant gender differences in the observed transitions from cumulative 
lifetime use and the 12-months prevalence at second follow-up. But it is remarkable that 
none of those females initially classified as ‘user, no disorder’ had developed a disorder at 
follow-up, while 16 men have done so (Table 5).  
 
A comparison of the two age cohorts revealed significant differences for the courses of 
those initially diagnosed as ‘never using’ cannabis or ‘use/no disorder’ (Table 5). Of the 
initially abstinent participants from the older group, nearly all remained abstinent (97.6%), 
whereas only 90.5% of the initially abstinent younger participants remained non-users. 
Similarly, participants in the older cohort initially grouped as ‘use/no disorder’ mostly 
stopped their cannabis use (62.2%) or — less often — remained in the same group 
(37.7%); only 0.2% developed a disorder. But in the younger cohort, 4.0% of the baseline 
‘use/no disorder’ participants developed cannabis related disorders by second follow-up 
and the majority remained users without disorder (63.0%); only a minority had stopped 
their cannabis use at follow-up (33.1%).  
 
Table 6 summarizes the cumulative incidence use pattern in the sample (until 12 months 
prior the second follow-up) and the proportion of non-users at t2 (12- months status). The 
lower the cumulative lifetime cannabis use, the higher the probability that participants did 
not use this substance during the 12 months preceding the second follow-up.  
 
3.5. To what degree is cannabis use or the cessation of cannabis use associated with the 
use of other substances?  
 
Table 7 reveals substantial associations between use of other licit and illicit drugs and 
cannabis use status (12-months prevalence at second follow-up). Continuous cannabis 
users had the highest 12-month use of other substances, followed by ex-cannabis-users 
(who had not taken cannabis during the past 12 months) and never-users of cannabis 
described a comparatively low consumption of drugs. The risk of using licit (alcohol, 
nicotine) as well as illicit drugs was significantly higher for continuous cannabis users as 
well as ex-users of cannabis compared to never users of cannabis. Odds ratios were 
particularly high for continuous (and to a lesser degree for ex-)cannabis users to use 
certain illicit drugs (opioids, cocaine, stimulants, sedatives, hallucinogens); odds ratios 
were lower but still increased for licit drugs (alcohol and nicotine). But there was no 
tendency of a compensative increased drug use of exusers of cannabis: this group used 
other licit and illicit drugs distinctly less often than those who had continued to use 
cannabis.  
 
4. Discussion  
 
In this paper data on the natural course of cannabis use, abuse and dependence over four 
years are presented, from a prospective-longitudinal representative community sample of 
2446 German adolescents, aged 14–24 years at baseline and 17–28 years at the second 
follow-up. The data presented here are comparable to US studies (e.g. Kessler et al., 1994; 
Warner et al., 1995) with regard to the design, sampling, data-analysis and instruments 
employed. Data were collected in personal interviews with an established reliable and 
valid standardized, computerized instrument (M-CIDI; Wittchen and Pfister, 1997; 
Lachner et al., 1998; Reed et al., 1998).  
 
4.1. Limitations of the study  
 
Some limitations of the study should be considered:  
 
1. Interpretation of some of the analyses for cannabis abuse and dependence is hampered 
by the fact that relatively few cases developed a cannabis disorder.  
2. Some attrition occurred from baseline to t2-followup that might have had an effect on 
the data. For example, users of any illegal drugs and participants with drug use disorders 
had a slightly but non-significant higher probability of not participating at the second 
follow-up (OR=1.5–1.7). Further, 102 participants of the study did not want to answer to 
questions about illicit drug use at one or more of the assessments. This potential selective 
attrition might have resulted in the description of a more favorable pattern of course for 
cannabis use, abuse and dependence.  
3. Cannabis users in the US on average use more of the drug; therefore, German ‘heavy 
use’ is not equivalent to US ‘heavy use’ (e.g. Kandel and Chen, 2000).  
4. Complexity of the field work resulted in a relatively variable follow-up length (range: 
34–50 months). Therefore, follow-up incidence data are reduced in their precision because 
they refer to varying time-intervals.  
5. Because of the focus of our study on early stages of substance use, the younger cohort 
was assessed three times (t0–t1–t2), the older group only two times (t0–t2). Therefore, 
higher estimations of use, abuse and dependence in the younger cohort could be related to 
the shorter follow-up intervals of the younger group, which reduces the chance of recall 
bias.  
 
4.2. Prevalence of cannabis use and disorders in Germany  
 
The overall cumulative lifetime incidence rate of 47% for cannabis use at the second 
follow-up for our then 17–28 year old participants is similar to estimates found in US or 
French studies for this age group (Anthony et al., 1994: 15–24 year olds: 36.5%; Chabrol 
et al., 2000: 16–20 year olds: 49%), but is higher than the federal German prevalence 
estimates of 26% for 21–24 year old adults in West Germany in 1995 (Kraus et al., 1998) 
and results from Greece (Kokkevi et al., 2000: 18–24 year olds: 22%). Overall, ages 14–
20 are peak hazard ages for initiation of cannabinoid use, and after age 16 is the peak risk 
period for developing abuse and dependence (Anthony et al., 1994; Kandel et al., 1997).  
 
Our cumulative lifetime incidence assessed at the second follow-up (t2) for CIDI-DSM-
IV-defined cannabis dependence in 17–28 year-olds (2.2%) is considerably lower than the 
5.6% cannabis dependence rate for 15–24 year olds found in recent US studies of this age 
group (Anthony et al., 1994). This raises important questions about why German young 
adults make the transition into dependence less frequently. Is this due to lower use rates, 
more favorable psychosocial factors, the established lower prevalence of associated 
psychopathological factors in German samples, or the lower prevalence of concomitant 
use of other drugs? We are currently examining these issues in a follow-up paper.  
 
While we did not find significant gender differences in the (previously published) 
analyses of the younger subsample (Perkonigg et al., 1999), we found gender differences 
in the full baseline data set (Perkonigg et al., 1998a) and in the four-year follow up data 
presented here for the complete sample. As most other researchers have reported, we 
found that men use and abuse cannabis more often than women do (Schumann and Kraus, 
1995; Kandel et al., 1997). Similar to other studies (Offord et al., 1996), females revealed 
in our second follow-up a slightly lower cumulative lifetime incidence (49.0% compared 
to 54.1% in male respondents), as well as distinctly lower rates for abuse and dependence 
(although the difference for dependence did not reach significance). All females with a 
cannabis use disorder developed the disorder before age 19 (dependence) or 23 years 
(abuse), while men’s incidence rate continued to increase throughout their twenties.  
 
4.3. Cannabis use — a transient phase-specific phenomenon?  
 
There is indeed a considerable variability in patterns of cannabis use and disorder over 
time. The proportion of subjects who had stopped cannabis use even after prolonged and 
heavy use is quite substantial. As expected from our previous analyses (Perkonigg et al., 
1999), our follow-up outcome analyses reveal that subjects with previous occasional 
cannabis use only (prior to the 12 months preceding second follow-up) had the highest 
probability of being grouped as non-users at second follow-up (12-months status: 74–
78%). Regular users (‘considerable use’: 39%; ‘heavy use’ without disorder: 25%) and 
subjects that had been diagnosed as having had a DSM-IV cannabis abuse (14%) or 
dependence (16%) were considerably less likely to have stopped their cannabis use during 
the 12 months preceding second follow-up.  
 
Since our sample includes the age span 14–24 years at baseline and 17–28 years at follow-
up, we have examined how these findings differ by age and cohort. About two-thirds 
(62%) of the older (birth cohort: 1970–77) cumulative lifetime cannabis users without 
disorder did not use cannabis during the 12 months preceding the second follow-up 
assessment; one third (38%) continued to use cannabis without developing a disorder, and 
only 0.2% developed an abuse (none developed dependence). But results were 
considerably different for the younger cohort (1977–81): only onethird (33%) of the users 
without disorder stopped their use, 63% continued as before, 3% developed abuse and 
0.7% developed cannabis dependence at follow-up (Table 5). These findings suggest (1) 
that users — and especially female users — who have not developed a DSM-IV cannabis 
use disorder by age 20 years have a fairly low probability of doing so at a higher age. (2) 
Incident use as well as continued use of cannabis is a characteristic of adolescents and 
young adults. Irrespective of the fact that there is a high proportion even among regular 
users after age 25 years in our sample that do not entirely stop taking the drug, these 
findings are partially consistent with the notion of cannabis use as a transient 
‘experimental period in adolescence’ (Kandel and Faust, 1975; Kandel and Logan, 1984; 
Hammer and Vaglum, 1990; Johnston et al., 1992; Silbereisen, 1997; Chen and Kandel, 
1998). Spontaneous changes from use to non-use occurred relatively often in our older 
subsample (aged 22–28 years at follow-up). The partiality of agreement is due to the fact 
that the length of cannabis use clearly stretches over almost a decade in our sample into 
the late 20s which makes the use of the word ‘transient’ somewhat questionable. But 
nevertheless the findings seem to be consistent with the speculation that a large proportion 
of cannabis use is of experimental ‘adolescence-limited’ nature (Moffitt, 1993) that for the 
most part stops during the 20s because of new responsibilities (job, relationship, 
parenthood).  
 
4.4. The bad news  
 
The good news about significant rates of spontaneous reduction or stop of cannabis use in 
almost 50% in our sample is offset by three problematic implications of our study.  
 
4.4.1. Increasing use of cannabis in younger German cohorts  
 
As has been found in studies in the US (Bachman et al., 1998; Bauman and Phongsavan, 
1999) and Greece (Kokkevi et al., 2000), we demonstrated a cohort effect with regard to 
the age of onset of cannabis (ab)use. The younger cohort (birth cohort 1977–81), tended to 
use and abuse cannabis more often and at an earlier age than those born 1970–77.  
 
4.4.2. Cannabis use is accompanied by an elevated use of other drugs  
 
Like several other researchers (e.g. Merrill et al., 1999; Fergusson and Horwood, 
2000a,b), we found that (continuous and ex-)cannabis users compared to non-users have 
significantly higher risks for use of other illicit substances like cocaine, stimulants, 
hallucinogens and opioids as well as for alcohol and nicotine. But increased risks do not 
necessarily prove a cause-effect relationship in the sense of the ‘gateway’ theory (Kandel 
and Faust, 1975). Although several studies show that use of other illicit substances usually 
is preceded by the use of cannabis (e.g. Fergusson and Horwood, 2000b), it is also 
obvious that the use of cannabis is usually preceded by the use of alcohol and nicotine 
(e.g. Kandel and Faust, 1975; Pederson and Skrondal, 1999). It is still an open question 
concerning whether cannabis use in adolescence causes use of other illicit drugs, or 
whether cannabis use is a marker for other factors that also cause the use of other illicit 
drugs (Merrill et al., 1999).  
 
Further, our analyses show that those former cannabis users who had stopped to use this 
substance at follow-up also had a lower follow-up use of other licit and illicit drugs 
compared to continuous users of cannabis — but they still tended to use other substances 
more often than never users of cannabis.   
 
4.4.3. Cannabis abuse and dependence tends to remain stable across four years  
 
More than 40% of the cumulative lifetime users that had fulfilled DSM-IV criteria for 
either cannabis abuse or dependence (prior to the 12 months before the second follow-up 
assessment) remained DSM-IV-cases of abuse or dependence at the 12-months follow-up. 
Additionally, only 0.2% of the older baseline cannabis users without disorder developed 
an abuse during follow- up (none developed a dependence), but a higher percentage of 
younger baseline users without disorder had become cases at 12-months follow-up (3.3% 
abuse, 0.7% dependence). Although it is not entirely clear whether this pattern is due to 
cannabis use per se or whether it is linked to the concomitant use of other substances, this 
finding raises clinical and public health concerns.  
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